Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to l-asparaginase

[1]  Y. Ko,et al.  Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  K. Tobinai,et al.  Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma. , 2017, Hematology/oncology clinics of North America.

[3]  S. Koscielny,et al.  Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. , 2015, European journal of cancer.

[4]  R. Suzuki,et al.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Sang‐wook Lee,et al.  Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Ohshima,et al.  Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Advani,et al.  Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. , 2009, The Lancet. Oncology.

[8]  S. Schuster,et al.  Selective apoptosis of natural killer‐cell tumours by l‐asparaginase , 2005, British journal of haematology.

[9]  M. Fukumoto,et al.  Frequent expression of P‐glycoprotein/MDR1 by nasal T‐cell lymphoma cells , 1995, Cancer.